Crohn's disease, 1st line biologic (NICE TA187) and LSCMMG Recommendation
NICE TA187 - Infliximab (review) and adalimumab for the treatment of Crohn's disease
Remicade®, Inflectra®, Remsima®
Infliximab is recommended as a treatment option for adults with severe active Crohn’s disease whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments), or who are intolerant of or have contraindications to conventional therapy.
Reason for decision: